Canaccord Genuity Group Issues Pessimistic Forecast for Teladoc Health (NYSE:TDOC) Stock Price

Teladoc Health (NYSE:TDOC) had its price objective cut by equities researchers at Canaccord Genuity Group from $12.00 to $10.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the health services provider’s stock. Canaccord Genuity Group’s price target indicates a potential upside of 90.37% from the company’s previous close.

Several other analysts also recently weighed in on TDOC. Leerink Partners cut their price objective on shares of Teladoc Health from $8.50 to $5.50 and set a “market perform” rating on the stock in a research report on Thursday. Piper Sandler reiterated an “overweight” rating and set a $9.00 price objective (down from $12.00) on shares of Teladoc Health in a research report on Thursday. Zacks Research lowered Teladoc Health from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Stifel Nicolaus cut their target price on Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Thursday. Finally, BMO Capital Markets reduced their price target on Teladoc Health from $8.00 to $5.00 and set a “market perform” rating for the company in a research report on Thursday. Four equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $7.80.

Teladoc Health Trading Down 1.8%

Shares of NYSE TDOC opened at $5.25 on Thursday. Teladoc Health has a 12-month low of $4.40 and a 12-month high of $9.94. The company has a market cap of $932.25 million, a price-to-earnings ratio of -4.61 and a beta of 2.12. The company has a current ratio of 2.70, a quick ratio of 2.60 and a debt-to-equity ratio of 0.71. The stock’s 50 day simple moving average is $5.99 and its 200 day simple moving average is $7.20.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $642.27 million during the quarter, compared to the consensus estimate of $635.33 million. Teladoc Health had a negative return on equity of 9.09% and a negative net margin of 7.92%.The firm’s revenue was up .3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Equities research analysts expect that Teladoc Health will post -1.16 EPS for the current year.

Insider Transactions at Teladoc Health

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $7.63, for a total value of $130,762.94. Following the sale, the chief executive officer directly owned 201,036 shares in the company, valued at approximately $1,533,904.68. The trade was a 7.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Adam C. Vandervoort sold 5,720 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total transaction of $42,842.80. Following the transaction, the insider owned 80,732 shares of the company’s stock, valued at approximately $604,682.68. This trade represents a 6.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,288 shares of company stock worth $251,684 over the last 90 days. 0.58% of the stock is currently owned by corporate insiders.

Institutional Trading of Teladoc Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Teladoc Health by 2.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock valued at $1,542,000 after buying an additional 5,235 shares in the last quarter. NewEdge Advisors LLC grew its holdings in shares of Teladoc Health by 1,278.7% in the 1st quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock worth $90,000 after acquiring an additional 10,485 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Teladoc Health by 5.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock worth $3,566,000 after acquiring an additional 24,124 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Teladoc Health during the first quarter worth $615,000. Finally, AlphaQuest LLC lifted its holdings in shares of Teladoc Health by 768.2% during the second quarter. AlphaQuest LLC now owns 32,341 shares of the health services provider’s stock valued at $282,000 after purchasing an additional 28,616 shares during the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 beat and narrower loss — Teladoc posted Q4 revenue of $642.3M (above Street) and a GAAP loss of $0.14/sh that was better than expected; management highlighted international and Integrated Care strength that helped offset weakness at BetterHelp. Teladoc Tops Q4 Earnings
• Positive Sentiment: Medium‑term revenue guidance and strategic initiatives — Management projected 2026 revenue of $2.47B–$2.59B and emphasized AI, insurance partnerships and international expansion as growth levers. That gives investors a multi‑year growth narrative beyond the quarter. 2026 Revenue Projection
• Positive Sentiment: Some analyst support remains — Bank of America upgraded TDOC to Buy (PT $7) and a few firms (Canaccord, Piper Sandler) kept positive/overweight stances despite trimming targets, signaling conviction among some analysts that upside exists from current levels. Analyst Reviews
• Neutral Sentiment: Earnings call details and metrics — Management’s earnings call and transcript provide context on segment trends (Integrated Care up, BetterHelp down) and KPI performance; useful for assessing sustainability of the beat. Earnings Call Highlights
• Negative Sentiment: Near‑term guidance and outlook caution — Q1 revenue guide (~$609M) and FY EPS guidance were conservative and Q1 revenue guidance came in below some estimates, creating uncertainty over short‑term growth and profitability. Q4 & Guidance Release
• Negative Sentiment: Multiple price‑target cuts — Several firms trimmed targets (examples: BMO to $5.00, Leerink to $5.50, Cowen/Wells Fargo/Stifel to $6.00 ranges), and some moved to market‑perform/hold — this fresh downdraft from sell‑side revisions pressures sentiment despite the beat. Analyst Target Moves

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.